MedWatch

Novo Nordisk objects to proposed reimbursement change for its fast-acting insulin in Denmark

Novo Nordisk does not concur with an assessment from the Danish Medicines Agency's Reimbursement Committee, which could result in the pharmaceutical company's fast-acting insulin Fiasp receiving conditional reimbursement instead of general reimbursement status.

Photo: Tidsvilde Stine/Ritzau Scanpix

The Reimbursement Committee, which advises the the Danish Medicines Agency on drug reimbursements, has proposed a reassessment of the drug Fiasp, and the company behind the product, Novo Nordisk, has voiced its opposition to the change.

The committee proposes that the fast-acting insulin should receive conditional reimbursement as opposed to a general reimbursement, which would mean that a smaller group of patients would have access to the drug.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs